Pfizer+-+-New York-based Pfizer+-+-Pfizer forecast revenue+-+-Pfizer Chief Financial+-+-Pfizer shares+-+-percent+-+-fellow drugmaker Allergan+-+-lower tax+-+-biggest U.S. drugmaker+-+-Wall Street expectations+-+-net income+-+-pain treatment Lyrica+-+-first-quarter net income+-+-lower-cost biotech drugs+-+-lower tax rates+-+-injectable drugs+-+-Zacks Investment Research+-+-shareholder-friendly capital allocation+-+-top-selling vaccine Prevnar+-+-external product development+-+-share repurchase program+-+-big sales jumps+-+-currency exchange rates+-+-device maker Hospira+-+-new breast cancer+-+-legacy Hospira operations+-+-Hospira cost savings+-+-Foicer Frank D'Amelio+-+-related pneumococcal infections+-+-initial cost savings+-+-strong operational performance+-+-cents+-+-new revenue+-+-higher revenue+-+-higher sales+-+-Allergan deal+-+-one-time gains+-+-injectable drugmaker+-+-premarket trading+-+-profit forecast+-+-drug Lyrica+-+-latest quarter+-+-higher spending+-+-business outlook+-+-new medicines+-+-one-time items+-+-financial forecasts+-+-strong performance+-+-European rivals+-+-prior forecast+-+-products business+-+-better-than-expected results+-+-new class+-+-big bet+-+-product manufacturing+-+-global market+-+-operational efficiency+-+-drug Ibrance+-+-Hospira acquisition+-+-currency rates+-+-Established businesses+-+-key driver+-+-chief executive+-+-Ian Read+-+-earnings-per-share guidance+-+-excellent progress+-+-analysts+-+-company+-+-range+-+-investors+-+-Viagra+-+-remainder+-+-record+-+-headquarters+-+-paper+-+-Ireland+-+-Inc.+-+-term+-+-doubling+-+-growth+-+-pneumonia+-+-marketing+-+-administration+-+-period+-+-changes+-+-infusion+-+-biosimilars+-+-impact+-+-Standard+-+-index+-+-taxes+-+-board+-+-statement+-+-chairman+-+-acquisitions